The overall ratings of six biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
TESARO, Inc.’s (TSRO) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, TSRO also gets F’s. The stock price has dropped 36.5% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. To get an in-depth look at TSRO, get Portfolio Grader’s complete analysis of TSRO stock.
This week, Trius Therapeutics, Inc.’s (TSRX) rating worsens to a D from the company’s C rating a week ago. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.
Protalix Biotherapeutics, Inc. (PLX) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Protalix BioTherapeutics is a biotechnology company that has developed plant cell culture technology and a bioreactor system. The stock gets F’s in Earnings Revisions and Sales Growth. For a full analysis of PLX stock, visit Portfolio Grader.
Array BioPharma (ARRY) is having a tough week. The company’s rating falls from a C to a D. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. The stock gets F’s in Cash Flow and Sales Growth. To get an in-depth look at ARRY, get Portfolio Grader’s complete analysis of ARRY stock.
Regeneron Pharmaceuticals, Inc. (REGN) experiences a ratings drop this week, going from last week’s C to a D. Regeneron Pharmaceuticals researches, develops and commercializes therapeutics to treat human disorders and conditions. The stock also rates an F in Earnings Momentum. The stock has a trailing PE Ratio of 42.40. For a full analysis of REGN stock, visit Portfolio Grader.
The rating of Discovery Laboratories, Inc. (DSCO) slips from a C to a D. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of DSCO stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.